Company intelligence / Profile preview

Purpurex

Aurora, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Purpurex is a biotechnology company focused on the development of small molecule therapeutics targeting the purinergic signaling pathway. The company's research centers on the P2X7 receptor, a key regulator of the inflammasome and the release of pro-inflammatory cytokines such as interleukin-1 beta. Founded by Dr. Charles Dinarello, a pioneer in cytokine research, Purpurex aims to treat a variety of inflammatory and metabolic disorders. Their approach leverages deep expertise in the biology of extracellular ATP to create highly specific inhibitors for chronic conditions where inflammation is a primary driver.

Therapeutic areas: RheumatologyImmunologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Purpurex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Purpurex.

Explore the full profile